Document is current
Any future updates will be listed below
-
Authors
Appleby, Niamh https://orcid.org/0000-0001-5063-9652
Eyre, Toby A.
Cabes, Maite
Jackson, Aimee
Boucher, Rebecca
Yates, Francesca
Fox, Sonia
Rawstron, Andrew
Hillmen, Peter
Schuh, Anna
-
Funding
Funding for this research was provided by:
Bloodwise (17003)
Acerta (ESR-CL-802)
- License Information
-
More Information
Article History
Received: 5 April 2019
Accepted: 14 May 2019
First Online: 20 May 2019
Ethics approval and consent to participate
: Ethics approval for the trial was obtained from the Research Ethics Service Committee (REC) South Central Oxford B. REC reference number: [18/SC/0634]. Initial REC approval was given on the 31-Jan-2019 (protocol v2.0), the current protocol v3.0 was approved 04-Mar-2019 via substantial amendment 1.0. The application and approval includes the following study centres (listed alphabetically) Bart’s Health NHS Trust; Belfast Health and Social Care; Cardiff and Vale Health Board; The Christie NHS Foundation Trust; The Clatterbridge Cancer Centre NHS Foundation Trust; NHS Greater Glasgow and Clyde; Kings College Hospitals NHS Foundation Trust; Leeds Teaching Hospitals NHS Trust; Nottingham University Hospitals NHS Trust; Oxford University Hospitals NHS Foundation Trust; The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; University College London Hospitals NHS Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals of Leicester NHS Trust; University Hospitals Southampton NHS Foundation Trust.All patients provide written informed consent to participate.
: Not applicable.
: NA: Gilead: Honorarium; travel to scientific conferences.TAE: Roche: Honorarium, Gilead: Honorarium; Research support; travel to scientific conferences, Janssen: Honorarium, Abbvie: Honorarium; Travel to scientific conferences.AJ: None.RB: None.FY: None.SF: None.MC: None.AR: AbbVie: Honoraria, unrestricted educational grant; Gilead: Honoraria, unrestricted educational grant; Janssen: Honoraria, unrestricted educational grant; Pharmacyclics: Honoraria; Roche: Honoraria, unrestricted educational grant; Celgene: Honoraria, unrestricted educational grant; BD Biosciences: royalties.PH: AbbVie: Honoraria, unrestricted educational grant; Gilead: Honoraria, unrestricted educational grant; Janssen: Honoraria, unrestricted educational grant; Roche: Honoraria, unrestricted educational grant.AS: AbbVie: Honoraria; Gilead: Honoraria, unrestricted educational grant; Janssen: Honoraria, unrestricted educational grant; Roche: Honoraria.Study funding, including acalabrutinib without charge, has been provided by Acerta (funder number ESR-CL-802).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
